5.00
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $5.00, with a volume of 3.59M.
It is down -6.02% in the last 24 hours and down -24.81% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.32
Open:
$5.07
24h Volume:
3.59M
Relative Volume:
1.48
Market Cap:
$386.61M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.0488
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-17.36%
1M Performance:
-24.81%
6M Performance:
-18.57%
1Y Performance:
-50.88%
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALT
Altimmune Inc
|
5.00 | 386.61M | 409.00K | -101.35M | -71.49M | -1.64 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-28-25 | Initiated | William Blair | Mkt Perform |
Jan-08-25 | Initiated | Stifel | Buy |
Nov-12-24 | Initiated | UBS | Buy |
Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
Jan-24-24 | Initiated | Goldman | Neutral |
Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
Dec-01-22 | Initiated | Goldman | Buy |
Dec-29-21 | Resumed | Jefferies | Buy |
Jun-02-21 | Initiated | H.C. Wainwright | Buy |
Feb-11-21 | Initiated | Guggenheim | Buy |
Dec-14-20 | Initiated | Jefferies | Buy |
Nov-12-20 | Reiterated | B. Riley Securities | Buy |
Sep-25-20 | Initiated | B. Riley FBR | Buy |
Aug-14-20 | Initiated | Evercore ISI | Outperform |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
Feb-24-20 | Resumed | ROTH Capital | Buy |
Jul-19-19 | Initiated | ROTH Capital | Buy |
Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa
Altimmune rises as buyout rumors follow R&D updates - MSN
Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia
Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com
Altimmune soars amid takeover speculation - MSN
Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha
(ALT) Trading Advice - Stock Traders Daily
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga
Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India
Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView
Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India
Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates Altimmune stock with $25 target - Investing.com
Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook - TipRanks
Altimmune to test obesity drug for alcohol use disorder and related health conditions - TradingView
Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions - TradingView
SBI Securities Co. Ltd. Acquires New Shares in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World
Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq
Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan
Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):